

1 Combined oropharyngeal/nasal swab is equivalent to nasopharyngeal  
2 sampling for SARS-CoV-2 diagnostic PCR

3

4 Tania Desmet,<sup>a</sup> Peter De Paepe,<sup>a</sup> Jerina Boelens,<sup>b</sup> Liselotte Coorevits,<sup>b</sup> Elizaveta Padalko,<sup>b</sup>  
5 Stien Vandendriessche,<sup>b</sup> Isabel Leroux-Roels,<sup>b,c</sup> Annelies Aerssens,<sup>c</sup> Steven Callens,<sup>d</sup> Eva  
6 Van Braeckel,<sup>e</sup> Thomas Malfait,<sup>e</sup> Frank Vermassen,<sup>f</sup> Bruno Verhasselt,<sup>b,#</sup>

7

8 <sup>a</sup> Emergency Department, Ghent University Hospital, Belgium.

9 <sup>b</sup> Department of Medical Microbiology, Ghent University Hospital, Belgium.

10 <sup>c</sup> Department of Infection Control, Ghent University Hospital, Belgium.

11 <sup>d</sup> Department of Internal Medicine & Infectious diseases, Ghent University Hospital, Belgium.

12 <sup>e</sup> Department of Respiratory Medicine, Ghent University Hospital, Belgium.

13 <sup>f</sup> Department of Thoracic and Vascular Surgery, Chief Physician and Head of COVID-19 task  
14 force, Ghent University Hospital, Belgium.

15

16

17 *Running title:* Oropharyngeal-nasal swab for SARS-CoV-2 diagnostic PCR

18

19 *# Corresponding author:* Prof. Dr. B. Verhasselt; C. Heymanslaan 10, 9000 Gent, Belgium.

20 [Bruno.verhasselt@uzgent.be](mailto: Bruno.verhasselt@uzgent.be). Tel: 0032 9 332 22 26.

21 ABSTRACT

22

23 *Background:* Early 2020, a COVID-19 epidemic became a public health emergency of  
24 international concern. To address this pandemic broad testing with an easy, comfortable and  
25 reliable testing method is of utmost concern. The nasopharyngeal (NP) swab sampling is the  
26 reference method though hampered by international supply shortages. A new  
27 oropharyngeal/nasal (OP/N) sampling method was investigated using the more readily  
28 available throat swab.

29

30 *Methods:* In this prospective observational study 36 COVID-19 patients were tested with both  
31 a NP and combined OP/N swab for SARS-CoV-2 RNA by PCR. In hospitalized suspect  
32 patients, who tested negative on both swabs, extensive retesting was performed. The  
33 sensitivity of NP versus combined OP/N swab sampling on admission and the correlation  
34 between viral RNA loads recovered was investigated.

35

36 *Results:* 35 patients were diagnosed with SARS-CoV-2 by means of either NP or OP/N  
37 sampling. The paired swabs were both positive in 31 patients. The one patient who tested  
38 negative on both NP and OP/N swab on admission, was ultimately diagnosed on  
39 bronchoalveolar lavage fluid. A strong correlation was found between the viral RNA loads of  
40 the paired swabs ( $r = 0.76$ ;  $P < 0.05$ ). The sensitivity of NP and OP/N analysis in hospitalized  
41 patients ( $n = 28$ ) was 89.3% and 92.7% respectively.

42

43 *Conclusions:* This study demonstrates equivalence of NP and OP/N sampling for detection of  
44 SARS-CoV-2 by means of rRT-PCR. Sensitivity of both NP and OP/N sampling is very high  
45 in hospitalized patients.

## 46 INTRODUCTION

47

48 A pandemic of respiratory disease caused by SARS-CoV-2 began in Wuhan, China in  
49 December 2019 and quickly spread to every continent. On February 1<sup>st</sup>, 2020, the disease  
50 was declared a Public Health Emergency of International Concern (PHEIC) by the World  
51 Health Organization (WHO). (1) By mid-May 2020, over 4 million people were infected and  
52 almost 300,000 died.

53

54 Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) on nasopharyngeal  
55 swab material is typically used to confirm the clinical diagnosis. (1,2) Nasopharyngeal (NP)  
56 swab remains the reference sampling method, while recent studies suggest that nasal swab  
57 and saliva sampling may be nearly equivalent. ([https://www.who.int/publications-  
58 detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117);  
59 <https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html>);5-6)

60 The detection of SARS-CoV-2 in oropharyngeal swabs seems less sensitive. (7-12)

61

62 In order to address a pandemic, extensive mapping and therefore broad testing with an easy  
63 and comfortable sampling method is of utmost importance. In the context of an international  
64 shortage in nasopharyngeal swabs, the search for a suitable alternative is a global health  
65 priority. This study evaluates a new combined oropharyngeal/nasal (OP/N) sampling method  
66 using the more readily available throat swab.

## 67 METHODOLOGY

68

69 This prospective observational study was conducted at Ghent University Hospital, Belgium  
70 from April 7th to May 1st, 2020. Upon presentation at the emergency department, all patients  
71 with suspected COVID-19 (based on respiratory and inflammatory symptoms) in whom a NP  
72 test was indicated for diagnosis, were candidates for a combined OP/N swab, sampled  
73 according to a specific protocol, developed in Ghent University Hospital. At inclusion, no  
74 distinction was made based upon disease severity or the need for hospitalization. Hospitalised  
75 patients with highly suspect clinical and radiological features of COVID-19 and negative  
76 PCR-sample on admission were retested with an additional NP and/or anal swab and finally,  
77 if still tested negative, on bronchoalveolar lavage (BAL) fluid for definite PCR-diagnosis. In  
78 ambulatory patients no retesting was performed.

79

80 Specimens from OP/N were obtained by rubbing the oropharyngeal space twice at both sides  
81 of the uvula and placing the same swab into both nasal cavities until a slight resistance was  
82 felt (supposed midturbinate). NP sampling was performed after OP/N sampling in order not to  
83 ‘contaminate’ the midturbinate part of the nose by viral material from the nasopharynx as may  
84 be expected when performed in reversed order. Each swab was rotated three complete turns  
85 for optimal mucosal contact. For NP sampling a flexible mini tip flocced swab (in Amies  
86 transport medium or in universal transport medium (UTM)) was used (Cat. numbers 481CE  
87 and 305C respectively, Copan<sup>®</sup>, Italy). OP/N sampling was performed using a non-flexible  
88 flocced swab with normal tip (in Amies transport medium, Cat. number 480CE, Copan<sup>®</sup>).

89

90 rRTPCR for SARS-CoV-2 RNA was performed on both the NP swab and the OP/N swab  
91 according to Corman et al. (13) using NucliSens easyMag™ RNA extraction (bioMérieux,  
92 Marcy-l'Étoile, France) and one-step rRT-PCR (Qiagen One Step RT-PCR Kit, Cat. number  
93 210212, Qiagen, Hilden, Germany) on CFX96 cyclers (Bio-Rad, Hercules, USA). All tests  
94 were performed in-hospital on a daily basis. A cycle threshold (Ct) value below 50 was  
95 interpreted as positive for SARS-CoV-2 RNA.

96  
97 All clinical samples were tested for inhibition by adding 7.5 µl of Diagenode RNA extraction  
98 and inhibition Real-Time PCR control (Cat. Number DECR-CY-L100, Diagenode SA®,  
99 Belgium).

100  
101 Since retesting was not performed in the ambulant patient group, sensitivity of OP/N and NP  
102 sampling was considered in hospitalized patients only.

103  
104 Descriptive and relative frequencies were used to describe the distribution of cases. Since the  
105 data were paired, the Wilcoxon signed-rank test was used to assess differences between cycle  
106 threshold (Ct, considered as log<sub>2</sub> transformed data of quantity viral RNA load) in NP and  
107 OP/N specimens. The correlation between NP PCR Ct and OP/N PCR Ct was assessed using  
108 Spearman's rank correlation. Sensitivity was calculated by means of cross tabs. Specificity  
109 was found not to be relevant since not one false positive SARS-CoV-2 PCR-result was found  
110 in this trial period, in line with literature. (5) Due to the nature of this trial, assessing  
111 sensitivity without a negative control group, a calculation of the weighted kappa coefficient  
112 was not relevant. All analyses were performed using IBM® SPSS® Statistics version 26.

113  
114 The study was approved by the ethical review board Ghent University Hospital (BC-07662).

## 115 RESULTS

116

117 During the study period, 41 SARS-CoV-2 PCR-confirmed patients were diagnosed at Ghent  
118 University Hospital. Five patients were excluded because no OP/N swab was sampled upon  
119 admission. Seventy-five samples from the 36 remaining patients were analysed. The median  
120 age was 61 years (range, 22-90), 21 out of 36 patients (58%) were male and 28 (78%) patients  
121 were hospitalized. Overall, 35/36 patients were diagnosed with SARS-CoV-2 by means of  
122 either NP or OP/N sampling on admission. The paired swabs were both positive in 31  
123 patients. In two patients, NP swabs were positive (Ct 36.47 and 38.38) with negative OP/N  
124 swabs. In two other patients, OP/N swabs were positive (Ct 34.14 and 41.39) with negative  
125 NP swabs. The one patient who tested negative on both NP and OP/N swab at admission, was  
126 ultimately diagnosed on BAL fluid (Ct 35.80).

127

128 When the paired OP/N and NP samples were compared in the 31 patients who tested positive  
129 in both, the median Ct for SARS-CoV-2 PCR was not significantly different: 27.5 cycles  
130 (range, 15.7–40.4) in NP samples vs. 27.2 cycles (range, 14.1–40.2) ( $P = 0.576$ ) in OP/N  
131 samples.

132

133 Besides, a strong correlation was found between the Ct values of the paired swabs ( $r = 0.76$ ;  $P$   
134  $< 0.05$ ) (Figure 1). From the 28 hospitalized patients, 27 were diagnosed by means of either  
135 NP (25) or OP/N (26) sampling. Thus, when considering a PCR positive result on BAL fluid  
136 as the ultimate confirmation of COVID-19 diagnosis, sensitivity of NP and OP/N analysis  
137 were 89.3% and 92.7% respectively in hospitalized patients ( $n = 28$ ).

138 DISCUSSION

139

140 Nasopharyngeal swab is considered to be the reference sampling method in suspected  
141 COVID-19 patients. ([https://www.who.int/publications-detail/laboratory-testing-for-2019-](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117)  
142 [novel-coronavirus-in-suspected-human-cases-20200117](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117),  
143 <https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html>) In the  
144 context of an international shortage in nasopharyngeal swabs, the search for a suitable  
145 alternative is a burning issue. Moreover, given the need of extensive population testing, an  
146 easy and patient-friendly sampling method is preferred. Salivary sampling has been reported  
147 as a reliable tool to detect SARS-CoV-2 in COVID-19 patients. This study, however, did only  
148 include patients with severe to very severe disease and did not provide information on mildly  
149 or moderately ill patients. (6) Nasal sampling was proposed as an alternative to  
150 nasopharyngeal sampling, though appears to be inferior to nasopharyngeal sampling (9.1%  
151 false negatives). (5) Oropharyngeal (OP) sampling is less sensitive (compared both to  
152 nasopharyngeal and nasal sampling) according to several studies. Wang X. et al. (2020) and  
153 Wang W. et al. (2020) reported a positivity rate of OP sampling of 27% and 32% respectively  
154 in COVID-19 patients. Sensitivity results were not reported. (8,11)

155

156 To our knowledge, our study is the first to show that the molecular detection of SARS-CoV-2  
157 on combined OP/N swabs was non-inferior to nasopharyngeal sampling.  
158 ([https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117)  
159 [suspected-human-cases-20200117](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117), [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html)  
160 [nCoV/lab/guidelines-clinical-specimens.html](https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html)) We found a high correlation between the viral  
161 RNA loads of the paired OP/N and NP samples. Besides, the sensitivities of both NP and  
162 OP/N sampling in hospitalized patients were 89.3% and 92.7% respectively. Large

163 differences in sensitivity of NP sampling were published ranging from 63% to 73.3%. (Y.  
164 Yang - unpublished data,11,14) It should be mentioned however that, to our knowledge, no  
165 peer-reviewed studies or large trials regarding this subject are available. The gold standard to  
166 which tests under investigation are to be compared, is not clear and differs among various  
167 publications, although consensus seems to exist about the positioning of BAL fluid as the  
168 most reliable testing method. (Y. Yang, unpublished data)

169 This study, performed in symptomatic patients with a broad age range and various degrees of  
170 disease severity, demonstrates equivalence of NP and OP/N sampling for detection of SARS-  
171 CoV-2 by means of rRT-PCR. Sensitivity of both NP and OP/N sampling is very high in  
172 hospitalized patients. These results warrant further evaluation of the combined  
173 oropharyngeal/nasal testing strategy in pauci- or asymptomatic individuals in order to tackle  
174 the global shortage in NP swabs. In this context, the new sampling strategy described here  
175 was used by the Belgian Government to guide a national screening campaign in residential  
176 care centres.

177 ACKNOWLEDGEMENTS

178

179 *The authors do not have an association that might pose a conflict of interest.*

180 Desmet Tania: No conflict.

181 De Paepe Peter: No conflict.

182 Boelens Jerina: No conflict.

183 Coorevits Liselotte: No conflict.

184 Padalko Elizaveta: No conflict.

185 Vandendriessche Stien: No conflict.

186 Leroux-Roels Isabel: No conflict.

187 Aerssens Annelies: No conflict.

188 Van Braeckel Eva: No conflict.

189 Malfait Thomas: No conflict.

190 Callens Steven: No conflict.

191 Vermassen Frank: No conflict.

192 Verhasselt Bruno: No conflict.


193 REFERENCES

194

- 195 1 Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R,  
196 Niu P, Zhan X, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel  
197 Coronavirus Investigating and Research Team. 2020. A novel coronavirus from  
198 patients with pneumonia in China, 2019. *N Engl J Med* 382(8): 727–733.
- 199 2 Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y,  
200 Zhao Y, Li Y, Wang X, Peng Z. 2020. Clinical characteristics of 138 hospitalized  
201 patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA. In*  
202 *press* 2020.1585.
- 203 3 World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-  
204 nCoV) in suspected human cases. Interim guidance. 19 March 2020. Accessed on  
205 April 29, 2020. [https://www.who.int/publications-detail/laboratory-testing-for-2019-](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117)  
206 [novel-coronavirus-in-suspected-human-cases-20200117](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117).
- 207 4 Centers for Disease Control and prevention. Interim Guidelines for Collecting,  
208 Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019  
209 (COVID-19). Accessed on April 29, 2020. [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html)  
210 [nCoV/lab/guidelines-clinical-specimens.html](https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html)
- 211 5 Péré H, Podglajen I, Wack M, Flamarion E, Mirault T, Goudot G, Hauw-Berlemont C,  
212 Le L, Caudron E, Carrabin S, Rodary J, Ribeyre T, Bélec L, Veyer D. 2020. Nasal  
213 swab sampling for SARS-CoV-2: A convenient alternative in time of nasopharyngeal  
214 swab shortage. *J. Clin. Microbiol* 58(6): e00721–20.
- 215 6 Azzi L, Carcano G, Gianfagna F, Grossi P, Dalla Gasperina D, Genoni A, Fasano M,  
216 Sessa F, Tettamanti L, Carinci F, Maurino V, Rossi A, Tagliabue A, Baj A. Saliva is a  
217 reliable tool to detect SARS-CoV-2. 2020. *J Infect. In press*. 2020.04.005.

- 218 7 Lin C, Xiang J, Yan M, Li H, Huang S, Shen C. Comparison of throat swabs and  
219 sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus  
220 (SARS-CoV-2)-infected pneumonia (COVID-19). 2020. Clin Chem Lab Med. *In*  
221 *press*. 2020-0187.
- 222 8 Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. 2020. Detection of SARS-CoV-  
223 2 in different types of clinical specimens. JAMA. Research letter. *In press*. 2020.3786.
- 224 9 Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J,  
225 Guo Q, Song T, He J, Yen HL, Peiris M, Wu J. 2020. SARS-CoV-2 viral load in upper  
226 respiratory specimens of infected patients. Letter to the editor. N Engl J Med 382(12):  
227 1177–1179.
- 228 10 Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, Zhang M, Wang Z, Xing L, Wei J,  
229 Peng L, Wong G, Zeng H, Wu W, Liao M, Feng K, Li J, Yang Q, Zhao J, Zhang Z,  
230 Liu L, Liu Y. 2020. Evaluating the accuracy of different respiratory specimens in the  
231 laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infection.  
232 MedRxiv; <https://www.medrxiv.org/content/10.1101/2020.02.11.20021493v2>
- 233 11 Wang X, Tan L, Wang X, Wang X, Tan L, Wang X, Liu W, Lu Y, Cheng L, Sun Z.  
234 2020. Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2  
235 detection in 353 patients received tests with both specimens simultaneously. Int J  
236 Infect Dis 94: 107–109.
- 237 12 Vermeiren C, Marchand-Senécal X, Sheldrake E, Bulir D, Smieja M, Chong S, Forbes  
238 SD, Katz K. 2020. Comparison of Copan Eswab and FLOQswab for COVID-19 PCR  
239 diagnosis: working around a supply shortage. J. Clin. Microbiol 58(6): e00669–20.

- 240 13 Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Kw Chu D, Bleicker T,  
241 Brünink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B,  
242 van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M,  
243 Goossens H, Reusken C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel  
244 coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 25(3): 23–31.
- 245 14 Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, Dittrich S,  
246 Yansouni CP. 2020. Diagnostic Testing for Severe Acute Respiratory Syndrome-  
247 Related Coronavirus-2: A Narrative Review. *Ann Intern Med*. *In press*. M20-1301.



*Figure 1* - Correlation of viral RNA load (log<sub>2</sub> transformed as threshold cycles) in nasopharyngeal sampling and oropharyngeal/nasal sampling. R =0.76.